As is the case for TSLP inhibition, clinical studies assessing airway biospecimens and neutrophil-related outcomes are needed to determine the impact of IL-33 blockade on neutrophil-related processes and clinical outcomes in COPD (Table 2). The gene discussed is TSLP; the disease is chronic obstructive pulmonary disease.